Previous studies reported that HER2 overexpression was an independent predictor of invasive disease and poor prognosis, indicating that HER2 expression might be associated with an important pathway through which DCIS lesions may progress toward invasive lesions (18, 21, 41). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.